Fondaparinux as an alternative therapy in heparin-induced delayed-type hypersensitivity skin lesions.
Alix C
AC
O'Meara
Franziska
F
Demarmels Biasiutti
Marc
M
Heizmann
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D000077425:Fondaparinux; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced*; D007279:Injections, Subcutaneous; D008297:Male; D017762:Nadroparin / Q000008:administration & dosage / Q000009:adverse effects*; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy*; D011134:Polysaccharides / Q000627:therapeutic use*; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D000925:Anticoagulants; D017762:Nadroparin; D011134:Polysaccharides; D000077425:Fondaparinux